e-Therapeutics uses its proprietary technology to analyse drug compounds  for pharmaceutical and biotechnology companies. Its techniques accurately predict the holistic effects of compounds on biological systems. The technology is patented, allowing e-Therapeutics to offer a range of unique services. These include:

• determining the mode of action of drugs,
• predicting candidate efficacy,
• identifying appropriate positioning against competitive drugs,
• identifying potential toxicity, safety and tolerance problems, and
• characterising possible drug interactions.

in silico → in vitro → in vivo

Clients are then able to make more informed judgements regarding the value of their candidates before committing further investment. e-Therapeutics’ reports provide clarity and additional information to support patent applications. In addition to the analytical services, e-Therapeutics can use its unique capabilities to collaborate with partners in a variety of ways, including:

• licensing e-Therapeutics’ proprietary compounds
• assisting with commercialisation and regulatory approval in worldwide markets
• establishing alternative therapeutic uses for compounds and compound libraries
• collaborative service provision

e-Therapeutics’ in-silico techniques enable rapid efficacy and toxicity indications at a fraction of the cost of traditional discovery methods. The company is responsive and agile so can meet tight deadlines within agreed budgets.